Clinical Trials Logo

Clinical Trial Summary

The principle is to propose dedicated monthly screening days bringing together the health personnel involved (hepatologist, addictologist, nurse in charge of the program, addictology nurse and social worker) and to propose appropriate management for each situation assessed.


Clinical Trial Description

1. Information on screening, the days are announced by : - Mailing to health professionals in the Haute-Vienne Department, - Announcement to the different professional orders concerned (doctors, pharmacists, midwives, nurses, etc.), - Flyers and posters in health care facilities, - Distribution in the AddictLim network newsletter (pharmacists, nurses, social workers members), - Various: Liaison team, health delegate of the network, intranet site of the hospital, CCAS, AMPA, day care centers. 2. Conduct of a SCANVIR day in the non-conventional structure " Hors les murs " : Each patient presenting during the screening day will have an individualized welcome. Addictological and hepatological data will be collected throughout the process by the various workers on the individual Scanvir form (attached). 1. The patient accepts one or more of the examinations proposed as part of the routine care. After information, he/she does not object to the collection of his/her personal data. 2. One or more TRODs and a FibroScan® are performed by the nurse in charge of the care pathway and/or the facility. 3. Performing, by the biologist or the authorized person, the delocalized PCR in case of positive HCV TROD 4. Consultation with the hepatologist, who gives the results of the TROD and FibroScan® in a closed and dedicated place where the confidentiality of exchanges is guaranteed. 5. A written document with the results of the TROD and FibroScan® and GeneXpert is given to the patient. Method for routine management of patients according to results : 1. HCV HBV HIV TROD are negative and FibroScan® > 7.1 KPa: The patient meets directly with the hepatologist to screen for risk factors for chronic liver disease (alcohol, medications ...). 2. The HCV HBV HIV TROD are negative and the FibroScan ® < 7.1 KPa : The nurse at the facility reviews with the patient the modes of transmission of the viruses and discusses with him/her risk reduction and harm reduction and what to do in case of recent exposure. 3. Positive HCV TROD: The hepatologist offers to do an immediate and on-site HCV RNA by delocalized PCR (GeneXpert). If the HCV RNA is positive, HCV treatment is started immediately (excluding comorbidity). An appointment is proposed 3 months after treatment to control the cure by delocalized PCR on site (RVS12) 4. HIV or HBV TROD positivity: The hepatologist proposes to do immediately and on site a complete blood test (HIV serology, HBV serologies (HBsAg, HBcAb, HBsAb) by the nurse present, assesses other risk factors and schedules an appointment for the results and management. For all situations, a prevention action to reduce the risks of transmission of HCV and HBV will be carried out at the same time. An anti-viral B vaccination may be offered. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05361603
Study type Observational
Source University Hospital, Limoges
Contact Marilyne DEBETTE-GRATIEN, MD
Phone 33 5 55 05 87 26
Email MARILYNE.GRATIEN@chu-limoges.fr
Status Recruiting
Phase
Start date May 24, 2017
Completion date February 14, 2030

See also
  Status Clinical Trial Phase
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Recruiting NCT04510246 - Link Hepatitis C Notifications to Treatment in Tasmania N/A
Completed NCT03413696 - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed NCT03109457 - Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
Completed NCT03118674 - Harvoni Treatment Porphyria Cutanea Tarda Phase 2
Completed NCT01458054 - Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults Phase 1
Completed NCT03740230 - An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
Completed NCT03426787 - Helping Empower Liver and Kidney Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Completed NCT00006301 - Immune Response to Hepatitis C Virus
Active, not recruiting NCT03949764 - The Kentucky Viral Hepatitis Treatment Study Phase 4
Completed NCT03365635 - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Phase 4
Recruiting NCT04405024 - Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients N/A
Completed NCT04525690 - Improving Inpatient Screening for Hepatitis C N/A
Completed NCT04033887 - Evaluation Study of RDTs Detecting Antibodies Against HCV
Withdrawn NCT04546802 - HepATocellular Cancer Hcv Therapy Study Phase 3
Active, not recruiting NCT02961426 - Strategic Transformation of the Market of HCV Treatments Phase 2/Phase 3
Completed NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Phase 3
Completed NCT02992184 - PoC-HCV Genedrive Viral Detection Assay Validation Study N/A
Completed NCT02869776 - Integrating HCV and HIV Screening During the Era of HIV Antigen Testing N/A